These studies confirmed the consistent reduction of MBP-specific T-cells following TCV and showed some indications of clinical efficacy as documented by the prolongation of the time to MS-progression in both RR-MS and SP-MS patients, as compared to the pre-vaccination rates. The gene discussed is MBP; the disease is myeloid sarcoma.